…Spotlights L’Artchem as a reliable solution in Nigeria’s malaria fight
As the global community marks World Malaria Day 2025, Chemiron Care Limited, one of Nigeria’s foremost pharmaceutical companies, has called on Nigerians to intensify the fight against malaria through timely diagnosis, effective treatment, and increased public awareness. It emphasised that the use of trusted antimalarial medications, such as its flagship brand L’Artchem, remains vital to achieving a malaria-free Nigeria.
The pharma company made the call on Friday, 25 April, which is a day recognised by the United Nations (UN), to raise awareness on malaria at the national and international levels, through a press release signed by its Chief Executive Officer, Suraj Jobanputra, and made available to Pharmanewsonline in commemoration of this year’s World Malaria Day.
This year’s theme, “Malaria ends with us: Reinvest, reimagine, reignite,” underscores the urgent need to reinvigorate global, national, and local responses to one of the world’s oldest and deadliest diseases.
World Malaria Day offers a sobering reminder of the disease’s turbulent history. In the 1960s, global eradication efforts were making headway until they were abruptly paused in 1969—resulting in millions of preventable deaths. It wasn’t until the late 1990s that the world recommitted to malaria control, preventing an estimated 2.2 billion cases and 12.7 million deaths since then. However, progress has since stalled, and malaria continues to claim a life nearly every minute—mostly in the WHO African Region.
In 2023 alone, more than 260 million malaria cases were recorded worldwide, with Africa accounting for 95 percent. Nigeria remains the epicentre of the crisis, bearing the world’s highest malaria mortality rate, particularly among children under five. Factors such as climate change, conflicts, humanitarian emergencies, and economic instability are severely disrupting malaria interventions and placing millions at greater risk.
Amid these challenges, Jobanputra disclosed that Chemiron has remained a dependable force in Nigeria’s health sector. For decades, he noted that the company has delivered quality, accessible, and effective pharmaceutical products. At the forefront of its malaria response is L’Artchem, a high-performance antimalarial therapy trusted by healthcare providers and patients alike.
Formulated through rigorous scientific research, “L’Artchem is known for its fast-acting and long-lasting relief. It provides up to three times faster parasite clearance compared to many alternatives and maintains a consistent 95 percent cure rate. Its gentle formulation reduces the risk of side effects, making it suitable for children, adults, and the elderly.
“It also offers broad protection against multiple malaria strains and ensures post-treatment coverage, reducing the chances of recurrence.”
He stressed that the fight against malaria requires more than institutional intervention. Personal responsibility is essential, and the public is urged to ensure that confirmed malaria cases are treated with reliable drugs especially in high-endemic areas where prompt and complete treatment can save lives and prevent transmission.
This year, the World Health Organisation and the RBM Partnership to End Malaria are urging stakeholders across the globe to rethink their strategies, reinvest in proven interventions, and reignite commitment at every level.
Jobanputra expressed Chemiron’s full alignment with this vision and reaffirmed their dedication to delivering dependable pharmaceutical solutions while advocating for a healthier, malaria-free Nigeria.
The fight against malaria is far from over, but with sustained efforts from government, healthcare professionals, pharmaceutical companies, and individuals, eliminating the disease is possible.
